Douglas J. Seith
Net Worth
Last updated:
What is Douglas J. Seith net worth?
The estimated net worth of Mr. Douglas J. Seith is at least $21,556,931 as of 13 Sep 2021. He owns shares worth $2,297,241 as insider, has earned $10,940,810 from insider trading and has received compensation worth at least $8,318,880 in AtriCure, Inc..
What is the salary of Douglas J. Seith?
Mr. Douglas J. Seith salary is $693,240 per year as Chief Operating Officer in AtriCure, Inc..
How old is Douglas J. Seith?
Mr. Douglas J. Seith is 59 years old, born in 1966.
What stocks does Douglas J. Seith currently own?
As insider, Mr. Douglas J. Seith owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
AtriCure, Inc. (ATRC) | Chief Operating Officer | 64,711 | $35.5 | $2,297,241 |
What does AtriCure, Inc. do?
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Douglas J. Seith insider trading
AtriCure, Inc.
Mr. Douglas J. Seith has made 15 insider trades between 2013-2021, according to the Form 4 filled with the SEC. Most recently he sold 21,444 units of ATRC stock worth $1,619,880 on 13 Sep 2021.
The largest trade he's ever made was exercising 58,112 units of ATRC stock on 13 Jun 2017. As of 13 Sep 2021 he still owns at least 64,711 units of ATRC stock.
AtriCure key executives
AtriCure, Inc. executives and other stock owners filed with the SEC:
- Mr. Douglas J. Seith (59) Chief Operating Officer
- Mr. Justin J. Noznesky (47) Chief Marketing & Strategy Officer
- Mr. Michael H. Carrel (54) Chief Executive Officer, Pres & Director
- Mr. Salvatore Privitera J.D. (58) Chief Technical Officer
- Ms. Angela L. Wirick CPA (47) Chief Financial Officer